Suppr超能文献

司地美芬酯/右美芬酯对注意缺陷多动障碍儿童睡眠的影响。

Serdexmethylphenidate/dexmethylphenidate effects on sleep in children with attention-deficit/hyperactivity disorder.

作者信息

Mattingly Greg W, Childress Ann C, Cutler Andrew J, Estrada José, Corliss Meg

机构信息

Washington University School of Medicine, Midwest Research Group, St. Louis, MO, United States.

Center for Psychiatry and Behavioral Medicine, Las Vegas, NV, United States.

出版信息

Front Psychiatry. 2023 Jun 23;14:1193455. doi: 10.3389/fpsyt.2023.1193455. eCollection 2023.

Abstract

INTRODUCTION

Sleep-related problems are common in children with attention-deficit/hyperactivity disorder (ADHD). Sleep disorders are also side effects of all stimulant ADHD medications. Serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) is a once-daily treatment approved for patients age 6 years and older with ADHD. In this analysis, sleep behavior was assessed during SDX/d-MPH treatment in children with ADHD.

METHODS

In a 12-month, dose-optimized, open-label safety study in 6- to 12-year-old participants (NCT03460652), a secondary endpoint was assessment of sleep behavior based on the Children's Sleep Habits Questionnaire (CSHQ) consisting of 8 sleep domains (bedtime resistance, sleep onset delay, sleep duration, sleep anxiety, night wakings, parasomnias, sleep-disordered breathing, and daytime sleepiness). This analysis examined the individual sleep domains in the 12-month safety study.

RESULTS

Of 282 participants enrolled, 238 were included in the sleep analysis. At baseline, mean (SD) CSHQ total sleep disturbance score was 53.4 (5.9). After 1 month of treatment, the mean (SD) CSHQ total score significantly decreased to 50.5 (5.4); least-squares mean change from baseline was -2.9 (95% CI: -3.5 to -2.4;  < 0.0001) and remained decreased up to 12 months. Mean sleep-score improvements from baseline to 12 months were statistically significant ( < 0.0001) for 5 of 8 sleep domains, including bedtime resistance, sleep anxiety, night wakings, parasomnias, and daytime sleepiness. Parasomnias and daytime sleepiness sleep domains showed the greatest mean improvement from baseline to 12 months. Sleep onset delay and sleep duration scores increased from baseline to 12 months. No statistically significant worsening occurred from baseline in sleep duration and sleep-disordered breathing domains; however, worsening of sleep onset delay was statistically significant.

CONCLUSION

In this analysis of children taking SDX/d-MPH for ADHD, sleep problems did not worsen based on the mean CSHQ total sleep disturbance score. Statistically significant improvements in most CSHQ sleep domains were observed after 1 month and lasted for up to 12 months of treatment.

摘要

引言

睡眠相关问题在注意力缺陷多动障碍(ADHD)儿童中很常见。睡眠障碍也是所有ADHD兴奋剂药物的副作用。舍曲美他嗪/右美沙芬(SDX/d-MPH)是一种每日一次的治疗药物,已被批准用于6岁及以上的ADHD患者。在本分析中,对ADHD儿童在SDX/d-MPH治疗期间的睡眠行为进行了评估。

方法

在一项针对6至12岁参与者的为期12个月、剂量优化的开放标签安全性研究(NCT03460652)中,一个次要终点是基于儿童睡眠习惯问卷(CSHQ)对睡眠行为进行评估,该问卷由8个睡眠领域组成(就寝抵抗、入睡延迟、睡眠时间、睡眠焦虑、夜间觉醒、异态睡眠、睡眠呼吸障碍和日间嗜睡)。本分析在12个月的安全性研究中检查了各个睡眠领域。

结果

在纳入的282名参与者中,238名被纳入睡眠分析。基线时,CSHQ总睡眠障碍评分的平均值(标准差)为53.4(5.9)。治疗1个月后,CSHQ总分的平均值(标准差)显著降至50.5(5.4);与基线相比的最小二乘均值变化为-2.9(95%CI:-3.5至-2.4;P<0.0001),并在长达12个月的时间内持续下降。从基线到12个月,8个睡眠领域中的5个领域的平均睡眠评分改善具有统计学意义(P<0.0001),包括就寝抵抗、睡眠焦虑、夜间觉醒、异态睡眠和日间嗜睡。从基线到12个月,异态睡眠和日间嗜睡领域的平均改善最为显著。入睡延迟和睡眠时间评分从基线到12个月有所增加。睡眠时间和睡眠呼吸障碍领域与基线相比没有出现统计学上显著的恶化;然而,入睡延迟的恶化具有统计学意义。

结论

在本对服用SDX/d-MPH治疗ADHD的儿童的分析中,基于CSHQ总睡眠障碍评分,睡眠问题没有恶化。在治疗1个月后,观察到大多数CSHQ睡眠领域有统计学意义的改善,并持续长达12个月。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f645/10327472/195c48fc8873/fpsyt-14-1193455-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验